RESUMEN
Consult Online is a telemedicine system used to provide advice to Dutch tropical doctors. Set up in 2008 by the Dutch Association of Tropical Doctors in Training, it aims to support tropical doctors who would otherwise not have access to specialist consult. By logging onto the website www.tropenopleiding.nl, they can consult over 50 experts from 17 different specialties, most of whom are Dutch specialists who have previously worked as tropical doctors. Four years after its start, Consult Online was evaluated: it had received 146 consultations from 15 different countries. Over half of these (54%) had been answered the same day; 79% within two days. The average number of reactions to a consultation was 3. In this way, Consult Online makes it possible to provide expert advice to doctors of patients in developing countries.
Asunto(s)
Internet/estadística & datos numéricos , Telemedicina , Medicina Tropical , Países en Desarrollo , Humanos , Países Bajos , Derivación y ConsultaRESUMEN
BACKGROUND: Total laparoscopic hysterectomy (TLH) is safe and cost effective in early stage endometrial cancer when compared to total abdominal hysterectomy (TAH). In non-randomised data it is often hypothesised that older and obese patients benefit most from TLH. Aim of this study is to analyse whether data support this assumption to advice patients, clinicians and policy makers. METHODS: Data of 283 patients enrolled in a randomised controlled trial comparing TAH versus TLH in early stage endometrial cancer were re-analysed. Randomisation by sequential number generation was done centrally, with stratification by trial centre. Using multivariate analysis, predictors of major complications and conversions to laparotomy were assessed. For the cost effectiveness analysis, subgroups of patients were constructed based on age and body mass index (BMI). For each subgroup, costs per major complication-free patient were estimated, using incremental cost effect ratios (extra costs per additional effect). RESULTS: Older (odds ratio (OR): 1.05; 1.01-1.09) and obese (OR: 1.05; 1.01-1.10) patients had a higher risk to develop complications, for both groups. In obese (OR: 1.17; 1.09-1.25) patients and patients with a previous laparotomy (OR: 3.45; 1.19-10.04) a higher risk of conversion to laparotomy was found. For patients>70 years of age and patients with a BMI over 35 kg/m2, incremental costs per major complication-free patients were 16 and 54 for TLH compared to TAH, respectively. CONCLUSION: In general, TLH should be recommended as the standard surgical procedure in early stage endometrial cancer, also in patients>70 years of age. In obese patients with a BMI>35 kg/m2 TLH is not cost effective because of the high conversion rate. A careful consideration of laparoscopic treatment is needed for this subgroup. Surgeon experience level may influence this choice.
Asunto(s)
Neoplasias Endometriales/cirugía , Histerectomía/métodos , Laparoscopía/economía , Laparotomía/economía , Obesidad/economía , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Análisis Costo-Beneficio , Femenino , Humanos , Histerectomía/economía , Histerectomía/instrumentación , Análisis de Intención de Tratar , Laparoscopía/métodos , Laparotomía/métodos , Persona de Mediana Edad , Obesidad/complicaciones , Evaluación de Procesos y Resultados en Atención de Salud , Complicaciones Posoperatorias/economía , Estudios RetrospectivosRESUMEN
The aim of this study was to investigate classical MHC class I and nonclassical MHC (human leukocyte antigen-G [HLA-G]) expression in a large cohort of patients with endometrial cancer, to determine the prognostic value of these cell surface markers and their relation with clinicopathological variables. Tissue microarrays containing epithelial endometrial carcinoma tissue from 554 patients were stained for classical and nonclassical MHC class I using the following monoclonal antibodies: 4H84 (anti-HLA-G), beta2-m (anti-beta-2-microglobulin) and HC-10 (MHC class I antigen heavy chain). Expression data were linked to known clinicopathological characteristics and survival. HLA-G upregulation and MHC class I downregulation in neoplastic cells was observed in 40% and 48%, respectively. Nonendometrioid tumor type, advanced stage disease (FIGO stage > or = II) and poorly or undifferentiated tumors were associated with MHC class I downregulation. Absence of HLA-G expression was independently associated with MHC class I downregulation. In univariate analysis, MHC class I downregulation was a predictor of worse disease-specific survival. Prognostic unfavorable tumor characteristics were correlated with downregulation of MHC class I expression in endometrial cancer cells. Furthermore, downregulated MHC class I has a negative impact on disease-specific survival, observed in a large cohort of patients with endometrial cancer. As there seems to be a relation between classical and nonclassical MHC class I molecules (HLA-G), further research is warranted to unravel this regulatory mechanism.
Asunto(s)
Neoplasias Endometriales/metabolismo , Neoplasias Endometriales/patología , Antígenos HLA/biosíntesis , Antígenos de Histocompatibilidad Clase I/biosíntesis , Anciano , Análisis de Varianza , Supervivencia sin Enfermedad , Femenino , Antígenos HLA-A/biosíntesis , Antígenos HLA-B/biosíntesis , Antígenos HLA-C/biosíntesis , Antígenos HLA-G , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Análisis de Matrices Tisulares , Microglobulina beta-2/biosíntesisRESUMEN
OBJECTIVE: Comparative evaluation of costs and effects of laparoscopic hysterectomy (LH) and abdominal hysterectomy (AH). DATA SOURCES: Controlled trials from Cochrane Central register of controlled trials, Medline, Embase and prospective trial registers. SELECTION OF STUDIES: Twelve (randomized) controlled studies including the search terms costs, laparoscopy, laparotomy and hysterectomy were identified. METHODS: The type of cost analysis, perspective of cost analyses and separate cost components were assessed. The direct and indirect costs were extracted from the original studies. For the cost estimation, hospital stay and procedure costs were selected as most important cost drivers. As main outcome the major complication rate was taken. FINDINGS: Analysis was performed on 2226 patients, of which 1013 (45.5%) in the LH group and 1213 (54.5%) in the AH group. Five studies scored > or =10 points (out of 19) for methodological quality. The reported total direct costs in the LH group ($63,997) were 6.1% higher than the AH group ($60,114). The reported total indirect costs of the LH group ($1,609) were half of the total indirect in the AH group ($3,139). The estimated mean major complication rate in the LH group (14.3%) was lower than in the AH group (15.9%). The estimated total costs in the LH group were $3,884 versus $3,312 in the AH group. The incremental costs for reducing one patient with major complication(s) in the LH group compared to the AH group was $35,750. CONCLUSIONS: The shorter hospital stay in the LH group compensates for the increased procedure costs, with less morbidity. LH points in the direction of cost effectiveness, however further research is warranted with a broader costs perspective including long term effects as societal benefit, quality of life and survival.
Asunto(s)
Histerectomía/economía , Histerectomía/métodos , Laparoscopía/economía , Laparoscopía/métodos , Laparotomía/economía , Laparotomía/métodos , Abdomen/cirugía , Costos y Análisis de Costo , Femenino , Hospitalización , Humanos , Evaluación de Resultado en la Atención de Salud/economía , Satisfacción del Paciente/economía , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto/economía , Resultado del TratamientoRESUMEN
OBJECTIVE: The presence of cervical involvement is important to establish a rational treatment for endometrial cancer patients. We investigated the value of preoperative endocervical curettage (ECC) in predicting cervical involvement. METHODS: Preoperative ECC of 290 patients with clinical stage I epithelial endometrial cancer was compared with histopathology of the uterus. RESULTS: Amongst all ECCs, 245 (84.5%) were negative and 45 (15.5%) were positive for endometrial cancer. In the uterine specimen, cervical involvement was found in 20% (58/290). PPV and NPV of ECC were 86.7% and 92.2%. False negative and false positive ECC occurred in 6.6% and 2.1%. Of all patients with positive ECC, 46.7% had FIGO stage II disease and 46.7% had extra uterine tumor spread (FIGO III, IV). CONCLUSION: ECC is an acceptable diagnostic tool to predict the presence or absence of cervical involvement in early stage endometrial cancer patients.
Asunto(s)
Dilatación y Legrado Uterino/métodos , Neoplasias Endometriales/patología , Neoplasias Endometriales/cirugía , Femenino , Humanos , Histerectomía , Persona de Mediana Edad , Estadificación de Neoplasias/métodos , Cuidados Preoperatorios/métodos , Estudios RetrospectivosRESUMEN
BACKGROUND: Traditionally standard treatment for patients with early stage endometrial cancer (EC) is total abdominal hysterectomy and bilateral salpingo oophorectomy (TAH+BSO) with or without lymph node dissection through a vertical midline incision. While TAH is an accepted effective treatment, it is highly invasive, visibly scarring and associated with morbidity. An alternative treatment is the same operation by laparoscopy. Though in several studies total laparoscopic hysterectomy (TLH+ BSO) seems a safe and feasible alternative approach in early stage endometrial cancer patients, there are no randomized data available yet. Furthermore, a randomized controlled trial with surgeons trained in laparoscopy is warranted in order to implement this technique in a safe manner. The aim of this study is to compare the treatment related morbidity, cost-effectiveness and quality of life in early stage endometrial cancer patients treated by laparoscopy versus the standard open approach. METHODS: A multi centre randomized clinical phase 3 trial, including 5 university hospitals and 15 regional hospitals in the Netherlands. Only gynecologists trained in performing a TLH are allowed to participate. INCLUSION CRITERIA: Patients with a clinical stage I endometrioid adenocarcinoma or complex atypical hyperplasia are randomized in a 2:1 allocation to receive TLH or TAH. The main outcome measure is the rate of major complications, as assessed by an independent clinical review board. In total, 275 patients are required to have 80% power at alpha-0.05 to detect a significant difference of 15% complication rate. Secondary outcome measures are 1) costs and cost-effectiveness, 2) minor complications, and 3) quality of life. All data from this multi center study are reported using case record forms. Data regarding quality of life, pain, body Image, sexuality and additional homecare are assessed with self reported questionnaires. DISCUSSION: A randomized multi center study in early stage endometrial cancer patients with inclusion criteria for patients and surgeons is designed and ongoing. Results will be presented at the end of 2009. TRIAL REGISTRATION: Dutch trial register number NTR821.